Stockscreener 앱 받기
35.91
0.44%
-0.0929
Tyra Biosciences Inc 주식(TYRA)의 최신 뉴스
Tyra Biosciences stock hits all-time high at 36.69 USD - Investing.com
ACMG meeting attendance advances FGFR3 inhibition work, Tyra Biosciences outlines - Traders Union
Tyra Biosciences (NASDAQ:TYRA) Sets New 12-Month HighHere's What Happened - MarketBeat
Trading the Move, Not the Narrative: (TYRA) Edition - Stock Traders Daily
Assessing Tyra Biosciences (TYRA) Valuation After Wider Full Year Loss And Earnings Update - Sahm
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Technicals: Is Tyra Biosciences Incs ROE strong enoughQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Update Recap: Is Tyra Biosciences Inc a strong candidate for buy and holdJuly 2025 Macro Moves & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing Tyra Biosciences (TYRA) Valuation After William Blair Coverage And Dabogratinib Progress - Sahm
Is Tyra Biosciences Inc stock undervalued right nowJuly 2025 Closing Moves & Growth Focused Stock Reports - baoquankhu1.vn
HC Wainwright Issues Optimistic Forecast for TYRA Earnings - Defense World
Tyra Biosciences stock reaches all-time high at 35.75 USD - Investing.com Nigeria
HC Wainwright Boosts Earnings Estimates for Tyra Biosciences - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year HighHere's Why - MarketBeat
Growth Stocks To Keep An Eye On – March 3rd - Defense World
Tyra Bioscience Raises $126 Million in Block Share Sale - TipRanks
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com Australia
Tyra Biosciences announces $126 million stock sale in block transaction By Investing.com - Investing.com Nigeria
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Tyra Biosciences has reached an agreement to privately issue 4 million common shares to a major investment management firm. - Bitget
Tyra Biosciences agreed to issue 4 million shares at $31.50 per share to a large investment management firmSEC filing - marketscreener.com
Tyra Biosciences Agreed To Issue 4 Million Shares At $31.50 Per Share To A Large Investment Management FirmSEC Filing - TradingView
Tyra Bios to sell 4.0M shares at $31.50 in $126M ATM block transaction - TradingView
Tyra Biosciences stock reaches all-time high at 35.75 USD By Investing.com - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.4%Here's What Happened - MarketBeat
TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead - TradingView
TYRA: Oral dabogratinib targets blockbuster opportunities in UTUC, NMIBC, and achondroplasia - TradingView
Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative? - Yahoo Finance
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
TYRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tyra Biosciences Q4 Loss Widens - marketscreener.com
Tyra Biosciences 10-K: Net loss $119.95M, EPS $(2.01) - TradingView
Tyra Biosciences (NASDAQ: TYRA) maps FGFR oncology and achondroplasia pipeline - Stock Titan
Tyra Biosciences (Nasdaq: TYRA) boosts R&D and outlines 2026 trial catalysts - Stock Titan
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - MarketBeat
TYRATyra Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan
Nasdaq Moves: What are the risks of holding Tyra Biosciences Inc2025 Market WrapUp & Stepwise Trade Execution Plans - baoquankhu1.vn
TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tyra Biosciences (TYRA) Valuation Under Review After ASCO Catalysts And Positive Analyst Attention - simplywall.st
Aug Swings: Is Tyra Biosciences Inc stock undervalued right nowMarket Risk Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
CEO Change: Is Tyra Biosciences Inc stock undervalued right nowPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
TYRA Should I Buy - Intellectia AI
Tyra Biosciences, Inc. (TYRA) Stock Analysis: 48.56% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
(TYRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
TYRA: Phase II trials for dabogratinib target NMIBC, UTUC, and achondroplasia, with key data due this year - TradingView
TYRA: FGFR3-targeted trials advance in NMIBC, achondroplasia, and UTUC, with key data expected this year - TradingView
Tyra Biosciences (TYRA) Price Target Increased by 14.97% to 48.96 - Nasdaq
ASCO-GU 2026: Key Oncology Updates From VIR, TARA, TYRA And Others - RTTNews
Tyra Biosciences stock hits all-time high at 34.0 USD - Investing.com India
Raymond James Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $55 - 富途牛牛
Tyra Biosciences stock hits all-time high at 34.0 USD By Investing.com - Investing.com Australia
Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month HighWhat's Next? - MarketBeat
Cantor Fitzgerald Initiates Tyra Bioscience at Overweight - marketscreener.com
POM Investors Have Opportunity to Lead PomDoctor Ltd. Securities Fraud Lawsuit - Weekly Voice
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium - PR Newswire
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - The Motley Fool
Tyra Biosciences, Inc. (TYRA) Stock Analysis: A Biotech With 57% Potential Upside - DirectorsTalk Interviews
0.18%
0.28%
자본화:
|
볼륨(24시간):